News
Two key protein structures in the body are being visualized for the first time, thanks in part to the latest technology in ...
Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...
When the antibiotic bedaquiline was introduced in 2012, it was the first new tuberculosis drug in over 40 years. Bedaquiline ...
SAN FRANCISCO — The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings ...
A team of researchers at the University of California, Davis, made small tweaks to the molecular structure of lysergic acid diethylamide (LSD) to see if it could be turned into an effective brain ...
The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...
Scientists have found a way to more than double the uptake ability of a chemical structure that can be used for scrubbing carbon dioxide from factory flues. Oregon State University scientists have ...
The researchers report that mean symptom domain scores were 59.3 for dupilumab versus 58.6 for placebo, mean activity scores were 66.3 versus 65.8, and mean impact domain scores were 38.2 versus 37.3.
11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent ® (dupilumab) pivotal trial (ADEPT) in bullous pemphigoid (BP) met the primary ...
and molecular outcomes and had an acceptable side-effect profile. 26,27 On the basis of these data, dupilumab was approved in the United States and European Union for the treatment of eosinophilic ...
Similarly, biologics such as the anti-IL-4/IL-13 antibody dupilumab are now available for the treatment ... For NCI-DTP compounds, chemical structures were imported into Maestro (Schrödinger) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results